ANN:ASXAnsell Limited Analysis

Ansell Limited (ANN.AX) is trading at AUD 29.69, just below its recent resistance around AUD 29.78 and well above the 20‑day SMA of AUD 27.79, indicating limited upside in the immediate term. The 14‑day RSI sits near 70, suggesting the stock is approaching overbought conditions, while the MACD remains bullish with the line above the signal. Volume trends are decreasing, and the overall trend is neutral, reinforcing a short‑term caution.
Fundamentally, the company posts a PE of 22.7 versus an industry average of 24.3, and a forward PE of 13.6, implying a valuation tilt toward the undervalued side. The DCF fair value of roughly AUD 7 is dramatically lower than the market price, but analyst consensus targets around AUD 35 point to a 19% upside. Margins are solid (gross 42%, operating 14%) and cash flow generation is healthy, though revenue growth is modest at 0.7%. The balance sheet shows a moderate debt‑to‑equity of 41.6% and a low beta of ~0.5, reflecting limited volatility. Geographic diversification across APAC, Europe, the Americas, and the Middle East mitigates regional shocks, while regulatory exposure in the medical‑devices space remains a medium‑level consideration. Overall, the stock appears undervalued with a stable earnings base, but short‑term price pressure and overbought signals temper aggressive buying.